What is the company's revenue performance for this quarter?

Total revenues significantly increased to $13.9 million in the third quarter of 2000, up from $7.2 million in the same period of 1999. This growth was driven by higher royalty and product sales, and a substantial increase in collaborative and other research and development revenue, largely due to a new agreement with Novartis.

Is the company profitable?

No, Vertex Pharmaceuticals reported a net loss of $24.9 million for the third quarter of 2000, compared to a net loss of $14.3 million in the prior year's quarter. The company expects to continue incurring operating losses due to significant ongoing investments in research and development, despite revenue growth.

How has the company's financing activities impacted its financial position?

Vertex raised substantial capital by issuing $175 million in convertible subordinated notes in March 2000 and an additional $345 million in September 2000. While these activities improved liquidity, the full conversion of the March 2007 notes in Q3 2000 resulted in a significant one-time expense of $14.4 million. As of September 30, 2000, the company held over $713 million in cash and investments.

What are the key drivers for future revenue and expenses?

Future revenue is expected to be driven by royalties from the approved HIV protease inhibitor Agenerase and payments from ongoing and future collaborative agreements. Key expenses will continue to be substantial investments in research and development for its drug pipeline and anticipated commercialization expenditures. The company also anticipates a material effect on its financial results from the implementation of new revenue recognition standards (SAB 101).

VRTX 10-Q Quarterly Report Q3 FY2000 — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals Inc. reported its third quarter and nine-month results for the period ending September 30, 2000. The company experienced a significant increase in total revenues, driven primarily by new and existing collaborative agreements, notably with Novartis and royalties from Agenerase. Despite revenue growth, Vertex continued to incur substantial net losses from operations, a trend expected to persist due to ongoing investments in research and development. A key event during the quarter was the full conversion of its 5% Convertible Subordinated Notes due March 2007, which resulted in a significant one-time "make-whole" payment expense. The company also successfully raised substantial capital through the issuance of new convertible subordinated notes in September 2000. Vertex's cash position remains strong, supported by these financing activities and existing investments, which are intended to fund its extensive research and development pipeline and anticipated operating losses.

Key Highlights

1Total revenues increased to $13.9 million for Q3 2000 from $7.2 million in Q3 1999, and to $58.4 million for the nine months ended September 30, 2000, from $23.7 million in the prior year period.
2Net loss for Q3 2000 was $24.9 million ($0.46 per share), compared to $14.3 million ($0.28 per share) in Q3 1999. The nine-month net loss was $28.4 million ($0.54 per share), an improvement from $42.7 million ($0.84 per share) in the prior year.
3A significant $14.4 million "make-whole" payment expense was recognized in Q3 2000 related to the full conversion of the 5% Convertible Subordinated Notes due March 2007.
4The company issued $345 million in 5% Convertible Subordinated Notes due September 2007 in September 2000, significantly boosting cash reserves.
5Cash and cash equivalents, along with short-term investments, totaled $713.3 million as of September 30, 2000, providing a strong liquidity position.
6Research and development expenses increased to $21.3 million in Q3 2000 from $16.4 million in Q3 1999, reflecting ongoing investment in the company's drug pipeline.
7Vertex expects to continue incurring operating losses beyond 2000 due to planned significant investments in research and development and anticipated commercialization expenditures.

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2000

Summary

Key Highlights

Frequently Asked Questions